Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Breast cancer and aging: Standing on the shoulders of a giant.

Karuturi MS, Sedrak MS, Magnuson A, Freedman R, Jatoi A, Smith BD, Kimmick GG.

J Geriatr Oncol. 2019 Jun 11. pii: S1879-4068(19)30185-7. doi: 10.1016/j.jgo.2019.05.019. [Epub ahead of print] Review.

PMID:
31201096
2.

Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.

Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA, Dees EC, Jolly TA, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Muss HB.

Cancer. 2019 Sep 1;125(17):2945-2954. doi: 10.1002/cncr.32175. Epub 2019 May 15.

PMID:
31090930
3.

Long-term decision regret surrounding systemic therapy in older breast cancer survivors: A population-based survey study.

Karuturi MS, Lei X, Yu S, Giordano SH, Swanick CW, Smith BD.

J Geriatr Oncol. 2019 Mar 30. pii: S1879-4068(18)30398-9. doi: 10.1016/j.jgo.2019.03.013. [Epub ahead of print]

PMID:
30940493
4.

Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.

Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K.

Clin Cancer Res. 2019 Jul 1;25(13):3996-4013. doi: 10.1158/1078-0432.CCR-18-3274. Epub 2019 Mar 13.

PMID:
30867218
5.

Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer.

Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH.

J Geriatr Oncol. 2019 Sep;10(5):705-708. doi: 10.1016/j.jgo.2019.01.024. Epub 2019 Feb 19.

6.

Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

Nyrop KA, Deal AM, Shachar SS, Basch E, Reeve BB, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA, Dees EC, Jolly TA, Reeder-Hayes KE, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Muss HB.

Oncologist. 2019 Jun;24(6):762-771. doi: 10.1634/theoncologist.2018-0590. Epub 2018 Dec 14.

PMID:
30552158
7.

Overall survival in older patients with cancer.

Edwards BJ, Zhang X, Sun M, Song J, Khalil P, Karuturi MS, Pang L, Geng Y, Dinney CP, Valero V, Champlin RE, Tripathy D.

BMJ Support Palliat Care. 2018 Sep 22. pii: bmjspcare-2018-001516. doi: 10.1136/bmjspcare-2018-001516. [Epub ahead of print]

PMID:
30244203
8.

Potentially inappropriate medication use in older patients with breast and colorectal cancer.

Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC Jr, Giordano SH.

Cancer. 2018 Jul 15;124(14):3000-3007. doi: 10.1002/cncr.31403. Epub 2018 Apr 24.

9.

Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review.

Kono M, Fujii T, Lim B, Karuturi MS, Tripathy D, Ueno NT.

JAMA Oncol. 2017 Sep 1;3(9):1266-1273. doi: 10.1001/jamaoncol.2016.4975. Review.

PMID:
28301631
10.

Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy.

Kono M, Fujii T, Lyons GR, Huo L, Bassett R, Gong Y, Karuturi MS, Tripathy D, Ueno NT.

Breast Cancer Res Treat. 2016 Nov;160(1):101-109. Epub 2016 Sep 23.

PMID:
27663436
11.

Chemotherapy-related cognitive impairment in older patients with cancer.

Loh KP, Janelsins MC, Mohile SG, Holmes HM, Hsu T, Inouye SK, Karuturi MS, Kimmick GG, Lichtman SM, Magnuson A, Whitehead MI, Wong ML, Ahles TA.

J Geriatr Oncol. 2016 Jul;7(4):270-80. doi: 10.1016/j.jgo.2016.04.008. Epub 2016 Jul 5. Review.

12.

Targeted agent use in cancer patients at the end of life.

Hui D, Karuturi MS, Tanco KC, Kwon JH, Kim SH, Zhang T, Kang JH, Chisholm G, Bruera E.

J Pain Symptom Manage. 2013 Jul;46(1):1-8. doi: 10.1016/j.jpainsymman.2012.07.007. Epub 2012 Dec 1.

13.

Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer.

Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR Jr.

Cancer. 2013 Jan 1;119(1):7-15. doi: 10.1002/cncr.27608. Epub 2012 Jun 26.

Supplemental Content

Loading ...
Support Center